

## Targeted Cancer Therapies: Advancing Personalized Oncology

**Khansari N\***

Department of Immunology, Tehran University of Medical Sciences, Iran

---

**Citation:** Khansari N. Targeted Cancer Therapies: Advancing Personalized Oncology. *Int Clin Med Case Rep Jour.* 2024;3(11):1-3.

**Received Date:** 03 November, 2024; **Accepted Date:** 06 November, 2024; **Published Date:** 10 November, 2024

**\*Corresponding author:** Nemat Khansari, Department of Immunology, Tehran University of Medical Sciences, School of Medicine, Tehran, Iran

**Copyright:** ©2024 Nemat Khansari. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

---

### OPINION

In the dynamic landscape of cancer treatment, the emergence of targeted cancer therapies has revolutionized the way we approach this complex and multifaceted disease. These personalized approaches target specific molecular alterations or pathways that drive tumor growth, offering the potential for more effective and less toxic treatments than traditional chemotherapy [1].

Advances in our understanding of cancer biology and the advent of sophisticated genomic technologies have paved the way for developing these targeted therapies. By mapping the unique mutations and molecular signatures within a patient's tumor, clinicians can select therapies tailored to the individual's specific cancer profile, ushering in a new era of personalized cancer medicine.

One of the critical challenges in targeted cancer therapy is the need for robust biomarkers to accurately identify the patients most likely to respond to these targeted agents. Precision medicine approaches leveraging patient-derived xenograft models have emerged as a promising tool to address this challenge. These models, which utilize patient-derived tumor samples to study drug responses in a pre-clinical setting, can help identify the optimal treatment regimens and guide the selection of patients most likely to benefit from targeted therapies.

The application of artificial intelligence [2] and machine learning in the clinical development of targeted cancer therapies further enhances our ability to personalize cancer care. These emerging digital technologies can help analyze vast amounts of genomic and clinical data, identify patterns, and predict treatment responses, enabling researchers and clinicians to develop more effective and personalized treatment strategies.

The advent of personalized cancer vaccines is another exciting frontier in targeted cancer therapies. Technological advancements in genomics, data science, and cancer immunotherapy now enable the rapid

mapping of mutations within a patient's tumor, the rational selection of vaccine targets, and the on-demand production of a therapy customized to the individual's unique tumor profile [3,4].

Alongside targeted therapies, cancer immunotherapy has also witnessed remarkable advancements. Personalized cancer vaccines, which leverage an individual's unique tumor mutations to stimulate an immune response, have shown promising results in early clinical trials, suggesting that this approach may soon become a cornerstone of personalized cancer treatment.

Personalized, targeted cancer therapy may not be equally effective for all cancer types or stages. This restricts the potential patient population that can benefit from this treatment approach. Limitation of Applicability to Certain Cancer Types and Stages [5]:

### **Cancer Type Considerations**

- Some cancers may have lower mutational burdens, providing fewer targetable neoantigens.
- Certain solid tumor types may be less immunogenic, reducing the likelihood of a targeted immunotherapy response. Cancers in specific anatomical locations may also be challenging to biopsy safely, limiting sample availability.

### **Disease Stage Impact**

- Early-stage cancers might lack sufficient tumor material for neoantigen identification.
- Advanced metastatic diseases may progress too rapidly for the targeted immunotherapy development process.

### **Immunological Factors**

- Patients with pre-existing immunodeficiencies may have a reduced capacity to respond to cancer therapies.
- Heavily pre-treated patients might have compromised immune systems, potentially limiting targeted immunotherapy efficacy.

### **Implications for Treatment Planning**

- There is a need for careful patient selection based on cancer type, stage, and individual immunological status.
- Integrating personalized, targeted immunotherapy into broader treatment strategies that account for these limitations is essential.

As we continue to deepen our understanding of cancer biology and harness the power of emerging technologies, the field of targeted cancer therapy is poised to transform the way we approach cancer care. By tailoring treatments to the unique characteristics of each patient's tumor, we can unlock the full potential of personalized oncology and improve clinical outcomes for individuals with cancer.

## REFERENCES

1. Krzyszczuk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berríos I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3-4):79-100.
2. Shah P, Kendall F, Khozin S, Goosen R, Hu J, Laramie JM, et al. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit Med. 2019;2:69.
3. Şahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. American Association for the Advancement of Science. 2018;359(6382):1355-60.
4. Feist M, Zhu Z, Dai E, Ma C, Liu Z, Giehl E, et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Springer Nature. 2020;28: 98-111.
5. Khansari N. Personalized targeted cancer therapies. Int J Clin Studies Med Case Res. 2024;46:3-5.